{"id":"W2537692172","doi":"10.1200/jco.2013.31.6_suppl.lba8","title":"Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Docetaxel; Dasatinib; Clinical endpoint; Internal medicine; Prostate cancer; Hazard ratio; Urology; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Gastroenterology; Cancer; Tyrosine kinase; Clinical trial; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002447966,0.001568444,0.002305683,0.0003702687,0.0003325282,0.001095501,0.0009263658,0.001222297,0.003386199],"category_scores_gemma":[0.001764356,0.0005412808,0.00190882,0.0004559003,0.001345951,0.001001127,0.0004539047,0.003023273,0.0005039114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001111149,"about_ca_system_score_gemma":0.001086879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001111444,"about_ca_topic_score_gemma":0.00350919,"domain_scores_codex":[0.9991133,0.0005767599,0.00004697052,0.0001115646,0.00006011214,0.00009137669],"domain_scores_gemma":[0.9987896,0.0002978114,0.0003688064,0.00007754123,0.00004633467,0.0004199042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9763634,0.003604459,0.001532465,0.0004062512,0.0008222543,0.00002880874,0.00003891112,0.0005013737,0.002324723,0.00006298748,0.0006406765,0.01367368],"study_design_scores_gemma":[0.8508735,0.1409947,0.005001452,0.00003974159,0.0009854292,0.00008940424,0.000036995,0.0005006792,0.000641545,0.0001451526,0.0006710552,0.00002031153],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923397,0.003939849,0.0002291957,0.0004923478,0.0001657734,0.0009221019,0.0008919752,0.00004663331,0.0009723453],"genre_scores_gemma":[0.9937912,0.001679092,0.0006896915,0.0005150253,0.0002036544,0.0009949983,0.001059837,0.00001660823,0.001049866],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003386199,"threshold_uncertainty_score":0.01294625,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1351763167605917,"score_gpt":0.4676910722699166,"score_spread":0.3325147555093249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}